文献速递类风湿关节炎痛风与晶体性关节病

阿片类药物流行:帮助风湿免疫科医生预防危机

The opioid epidemic: helping rheumatologists prevent a crisis.
PubMed 文献 · RMD Open · 2019-08-06

处方阿片类药物相关死亡在发达国家 endemic 增加,美国2016年每天超过46人死于处方阿片过量。多种慢性非癌性疼痛(骨关节炎、慢性下背痛、类风湿关节炎等)队列研究显示2%至8%患者接受强阿片治疗,近期法国、欧洲及美国相关学会发布推荐,强调准确评估疼痛、设定治疗目标、预先评估滥用风险及特定剂量或疗程后寻求专科意见。

要点

  • 处方阿片相关死亡在发达国家呈地方性增加,欧洲部分国家住院与死亡上升。
  • 慢性非癌性疼痛队列中2%至8%患者接受强阿片治疗。
  • 强阿片处方须遵循准确评估疼痛、设定目标、评估滥用风险及超量或超疗程寻求专科意见的原则。

核心结论

  • 处方阿片类药物相关死亡在发达国家呈地方性增加,风湿免疫科医生需遵循推荐以优化强阿片处方并预防死亡、滥用和误用风险。

研究设计与样本

  • 本文为综述,汇总发达国家处方阿片相关死亡数据、欧洲住院与死亡趋势、慢性非癌性疼痛队列研究及法国、欧洲和美国相关学会近期发布的推荐。

主要发现

  • 2016年美国每天超过46人死于涉及处方阿片的过量。
  • 欧洲数据显示接受强阿片治疗的患者数量增加,部分国家阿片中毒住院、滥用和死亡上升。
  • 多种慢性非癌性疼痛(骨关节炎、慢性下背痛、类风湿关节炎等)队列研究中,2%至8%患者接受强阿片治疗。

关键数值与推荐

  • 法国2016年法国疼痛研究与治疗学会推荐、2017年欧洲国际疼痛研究协会欧洲分会与美洲国际疼痛医师学会推荐均认同:阿片可用于慢性非癌性疼痛,但处方须遵循必要规则。
  • 推荐要求准确评估疼痛及其来源、制定治疗目标(疼痛、功能和/或生活质量)、预先评估滥用风险,并在超过特定剂量或疗程时获取专科意见。

临床怎么用

  • 风湿免疫科医生对慢性非癌性疼痛患者处方强阿片前应准确评估疼痛及来源并设定疼痛、功能和/或生活质量目标。
  • 处方前应评估滥用风险,超过特定剂量或疗程时寻求专科意见。

局限性

  • 原文未报告综述的检索策略、纳入研究数量及推荐的具体剂量或疗程阈值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

An endemic increase in the number of deaths attributable to prescribed opioids is found in all developed countries. In 2016 in the USA, more than 46 people died each day from overdoses involving prescription opioids. European data show that the number of patients receiving strong opioids is increasing. In addition, there is an upsurge in hospitalisations for opioid intoxication, opioid abuse and deaths in some European countries. This class of analgesic is increasingly used in many rheumatological pathologies. Cohort studies, in various chronic non-cancer pain (CNCP) (osteoarthritis, chronic low back pain, rheumatoid arthritis, etc), show that between 2% and 8% of patients are treated with strong opioids. In order to help rheumatologists prescribe strong opioids under optimal conditions and to prevent the risk of death, abuse and misuse, recommendations have recently been published (in France in 2016, the recommendations of the French Society of Study and Treatment of Pain, in 2017, the European recommendations of the European Federation of IASP Chapters and the American Society of International Pain Physicians). They agree on the same general principles: opioids may be of interest in situations of CNCP, but their prescription must follow essential rules. It is necessary to make an accurate assessment of the pain and its origin, to formulate therapeutic objectives (pain, function and/or quality of life), to evaluate beforehand the risk of abuse and to get a specialised opinion beyond a certain dose or duration of prescription.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Trouvin AP, Berenbaum F, Perrot S, et al. The opioid epidemic: helping rheumatologists prevent a crisis. RMD Open. 2019. PMID: 31452932. doi:10.1136/rmdopen-2019-001029

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。